British Journal of Cancer

Article	Citations
Comparison of the ADNEX and ROMA risk prediction models for the diagnosis of ovarian cancer: a multicentre external validation in patients who underwent surgery	242
wMKL: multi-omics data integration enables novel cancer subtype identification via weight-boosted multi-kernel learning	234
Exposure to low-level ambient air pollution and the relationship with lung and bladder cancer in older men, in Perth, Western Australia	136
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma	114
Cancer care for migrant people	113
Advancing radiomics from contrast-enhanced mammography in breast cancer	103
Tumor budding and lymphovascular invasion as prognostic factors in p16-positive oropharyngeal squamous cell carcinomas	102
Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis	101
MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemness	96
Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling	92
Patient attrition in Molecular Tumour Boards: a systematic review	92
Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition	85
Metastasis-associated fibroblasts in peritoneal surface malignancies	84
Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma	83
A novel circulating miRNA panel for non-invasive ovarian cancer diagnosis and prognosis	82
What kind of tumour rupture requires adjuvant therapy?	81
A DNA methylation signature for the prediction of tumour recurrence in stage II colorectal cancer	77
The role of PPARγ in prostate cancer development and progression	76
Reduced SKP1 and CUL1 expression underlies increases in Cyclin E1 and chromosome instability in cellular precursors of high-grade serous ovarian cancer	74
Morpholino-driven blockade of Dkk-1 in osteosarcoma inhibits bone damage and tumour expansion by multiple mechanisms	73
Non-coding RNAs as liquid biopsy biomarkers in cancer	71
Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers	70
Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306	70
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3	65
Standardised survival probabilities: a useful and informative tool for reporting regression models for survival data	65

Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms	64
Quantitative breast density analysis to predict interval and node-positive cancers in pursuit of improved screening protocols: a case–control study	64
Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing	63
ACE inhibitors and the risk of lung cancer—is there causality?	62
Two contrasting papers stimulate a commentary on the origins of tumour immunology, current cancer immunotherapies, and the future potential for cancer immunotherapy	62
Revitalising cancer clinical trials: definitely time for patient-centred reform	62
Intratumoural haematopoietic stem and progenitor cell differentiation into M2 macrophages facilitates the regrowth of solid tumours after radiation therapy	57
Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing	57
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma	57
CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer	57
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience	56
Anti-integrin αvβ6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis	56
A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis	54
Association between C-reactive protein and risk of overall and 18 site-specific cancers in a Japanese case-cohort	54
Age alone is not a barrier to efficacy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: analysis of 1138 patients from the UK and Ireland Co	53
RE: Reply to Rio-Vilariño and colleagues’ article and misconception about YAP1 Ser 397 phosphorylation function	52
Association between weight cycling and risk of colorectal cancer: a prospective cohort study	51
Predicting the clinical outcome of oral potentially malignant disorders using transcriptomic-based molecular pathology	51
Randomised controlled trial of breast cancer and multiple disease prevention weight loss programmes vs written advice amongst women attending a breast cancer family history clinic	51
A metabolic map and artificial intelligence-aided identification of nasopharyngeal carcinoma via a single-cell Raman platform	51
Immunoproteasome inhibition prevents progression of castration-resistant prostate cancer	49
Cancer therapy with decreased SARS-CoV-2 infection rates in cancer patients	49
Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy	49
Reply to Comment on: ‘Hypoxia differently modulates the release of mitochondrial and nuclear DNA’	48
Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation	47
Chronic oxidative stress adaptation in head and neck cancer cells generates slow-cyclers with decreased tumour growth in vivo	46
The DNA damage response in advanced ovarian cancer: functional analysis combined with machine learning identifies signatures that correlate with chemotherapy sensitivity and patient outcome	46
Circulating small extracellular vesicle-based miRNA classifier for follicular thyroid carcinoma: a diagnostic study	45
Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value	44
Risk of cancer following primary care presentation with fatigue: a population-based cohort study of a quarter of a million patients	44
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer	44
Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancer	44
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade	43
VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis	43
Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive	43
Extruded small extracellular vesicles: splinters of circulating tumour cells may promote cancer metastasis?	43
The dark side of synaptic proteins in tumours	42
Independent validation of a pre-specified four-kallikrein marker model for prediction of adverse pathology and biochemical recurrence	42
Long-term exposure to ambient air pollution and bladder cancer incidence in a pooled European cohort: the ELAPSE project	42
Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities	41
Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer	41
Pre-diagnosis tea and coffee consumption and survival after a diagnosis of ovarian cancer: results from the Ovarian Cancer Association Consortium	41
Proteogenomics drives therapeutic hypothesis generation for precision oncology	41
Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy	40
Use the term “infiltrative” instead of “replacement” when defining histopathological growth pattern in patients with liver cancer	40
Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database	40
Optimising treatment pathways for borderline and locally advanced pancreatic cancer: an adaptive personalised approach	40
Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases	39
Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer	39
Targeting acetate metabolism: Achilles’ nightmare	39

Comment on: “Hypoxia differently modulates the release of mitochondrial and nuclear DNA”	39
Circulating tumour cells in gastrointestinal cancers: food for thought?	39
A taxonomy of early diagnosis research to guide study design and funding prioritisation	38
BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK breast oncology setting: a randomised, non-inferiority trial	38
Circulating 25-hydroxyvitamin D and survival outcomes of colorectal cancer: evidence from population-based prospective cohorts and Mendelian randomisation	38
Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric cancer	38
Liquid biopsy: creating opportunities in brain space	37
The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients	36
Circulating miRNA panels as a novel non-invasive diagnostic, prognostic, and potential predictive biomarkers in non-small cell lung cancer (NSCLC)	36
Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis	36
Metabolic adaptations in prostate cancer	36
Consumption of olive oil and risk of breast cancer in U.S. women: results from the Nurses’ Health Studies	36
Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer	36
Tumorigenic role of tacrolimus through mTORC1/C2 activation in post-transplant renal cell carcinomas	35
The NHS England 100,000 Genomes Project: feasibility and utility of centralised genome sequencing for children with cancer	35
The prognostic value of combined measures of the systemic inflammatory response in patients with colon cancer: an analysis of 1700 patients	34
Potential role of the CD39-CD73 ATP-adenosine pathway in platelet mediated dissemination of circulating tumour cells	34
Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies	34
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10	33
Clinical impact of PET/MRI in oligometastatic colorectal cancer	33
HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial	33
AI-based smartphone apps for risk assessment of skin cancer need more evaluation and better regulation	32
A clinically practical model for the preoperative prediction of lymph node metastasis in bladder cancer: a multicohort study	32
An emerging role for BAG3 in gynaecological malignancies	32
Whole-exome and targeted gene sequencing of large-cell lung carcinoma reveals recurrent mutations in the PI3K pathway	32
Years of life lost due to cancer in the United Kingdom from 1988 to 2017	32
Deep learning-based pathology signature could reveal lymph node status and act as a novel prognostic marker across multiple cancer types	32
PFKFB3 works on the FAK-STAT3-SOX2 axis to regulate the stemness in MPM	32
TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer	32
Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma	32
Biomarker testing in cancer management- can one size fit all?	32
Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer	31
Cancer survivorship and risk of pregnancy complications, adverse obstetric outcomes, and maternal morbidities in female adolescents and young adults: a nationwide population-based study from Taiwan	31
The bovine dialysable leukocyte extract IMMUNEPOTENT CRP induces immunogenic cell death in breast cancer cells leading to long-term antitumour memory	31
MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer	31
Investigation of the gut microbiome, bile acid composition and host immunoinflammatory response in a model of azoxymethane-induced colon cancer at discrete timepoints	31
SIRT1 is an actionable target to restore p53 function in HPV-associated cancer therapy	30
Predicted leukocyte telomere length and risk of germ cell tumours	30
Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway	30
Organoid forming potential as complementary parameter for accurate evaluation of breast cancer neoadjuvant therapeutic efficacy	30
Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases	30
Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study	30
Comments on “Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer”	30
Prediction of response to neoadjuvant chemo-immunotherapy in patients with esophageal squamous cell carcinoma by a rapid breath test	30
Circulating tumour DNA: a challenging innovation to develop “precision onco-surgery” in pancreatic adenocarcinoma	29
Quantitative multiplexed imaging technologies for single-cell analysis to assess predictive markers for immunotherapy in thoracic immuno-oncology: promises and challenges	29
Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression	29
Increased cross-presentation by dendritic cells and enhanced anti-tumour therapy using the Arp2/3 inhibitor CK666	29
Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis	29
Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study	29
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)	29
The association of Health-Related Quality of Life and 1-year-survival in sarcoma patients—results of a Nationwide Observational Study (PROSa)	29
Significant decrease in interval colorectal cancer incidence after implementing immunochemical testing in a multiple-round guaiac-based screening programme	29
Surveillance after childhood cancer: are survivors with an increased risk for cardiomyopathy regularly followed-up?	28
Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma	28
An old friend with a new face: tRNA-derived small RNAs with big regulatory potential in cancer biology	28
CD20 expression, TrkB activation and functional activity of diffuse large B cell lymphoma-derived small extracellular vesicles	28
Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study	28
SBSN drives bladder cancer metastasis via EGFR/SRC/STAT3 signalling	28
The use of biomarkers and HPV genotyping to improve diagnostic accuracy in women with a transformation zone type 3	28
The tumour immune microenvironment in oesophageal cancer	28
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs’ development	27
Tumour-associated myeloid cells expressing IL-10R2/IL-22R1 as a potential biomarker for diagnosis and recurrence of pancreatic ductal adenocarcinoma	27
Alternative methods to measure breast density in younger women	27
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours	27
Understanding the impact of immune-mediated selection on lung cancer evolution	27
Blockade of TGF-β and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses	27
TGFβ carrying exosomes in plasma: potential biomarkers of cancer progression in patients with head and neck squamous cell carcinoma	27
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients	27
Comment on “Redefining cancer research for therapeutic breakthroughs”	27
Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer	27
Dietary intake of total, heme and non-heme iron and the risk of colorectal cancer in a European prospective cohort study	27
Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours	27
A cellular model provides insights into the pathogenicity of the oncogenic FOXL2 somatic variant p.Cys134Trp	26
Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodules	26
Cancer-specific tissue-resident memory T-cells express ZNF683 in colorectal cancer	26
Biparatopic anti-HER2 drug radioconjugates as breast cancer theranostics	26
‘Evaluation of adverse prognostic gene alterations & MRD positivity in BCR::ABL1-like B-lineage acute lymphoblastic leukaemia patients, in a resource-constrained setting	26
Solar ultraviolet radiation exposure, and incidence of childhood acute lymphocytic leukaemia and non-Hodgkin lymphoma in a US population-based dataset	26
Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma	26

Anti-PEc: Development of a novel monoclonal antibody against prostate cancer	26
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours	26
Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity	26
A Wnt-mediated phenotype switch along the epithelial–mesenchymal axis defines resistance and invasion downstream of ionising radiation in oral squamous cell carcinoma	26
Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents	26
Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges	25
Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients	25
Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade	25
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours	25
Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis	25
Tertiary lymphoid structures correlate with enhancement of antitumor immunity in esophageal squamous cell carcinoma	25
Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them	25
AIP: A double agent? The tissue-specific role of AIP as a tumour suppressor or as an oncogene	25
Body mass index and absolute lymphocyte count predict disease-free survival in Korean breast cancer patients	24
Socio-economic inequalities in cancer survival: how do they translate into Number of Life-Years Lost?	24
Cell proliferation, drug distribution and therapeutic effects in relation to the vascular system of solid tumours	24
A blood-based transcriptomic signature for noninvasive diagnosis of gastric cancer	24
Frequency of peripheral PD-1+regulatory T cells is associated with treatment responses to PARP inhibitor maintenance in patients with epithelial ovarian cancer	24
KDM1A, a potent and selective target, for the treatment of DNMT3A-deficient non-small cell lung cancer	24
TRIM21/USP15 balances ACSL4 stability and the imatinib resistance of gastrointestinal stromal tumors	24
A nationwide study of breast reconstruction after mastectomy in patients with breast cancer receiving postmastectomy radiotherapy: comparison of complications according to radiotherapy fractionation a	24
CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer	24
Prognostic benefit of TILs independent of clinicopathological and molecular factors	24
Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial	24
Targeting obesity-related dysfunction in hormonally driven cancers	24
Causal effects of gallstone disease on risk of gastrointestinal cancer in Chinese	24
A new perspective on the immune escape mechanism in HCC: onco-foetal reprogramming	23
The EXO1/Polη/Polι axis as a promising target for miR-3163-mediated attenuation of cancer stem-like cells in non-small cell lung carcinoma	23
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial	23
Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling	23
Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens	23
Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting	23
Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer	23
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)	23
CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer	23
The cost-effectiveness of risk-stratified breast cancer screening in the UK	23
Associations of diabetes, circulating protein biomarkers, and risk of pancreatic cancer	23
Vaccination and screening strategies to accelerate cervical cancer elimination in Norway: a model-based analysis	23
Transcriptome analysis reveals upregulation of immune response pathways at the invasive tumour front of metastatic seminoma germ cell tumours	23
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer	22
The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications	22
The mental health impacts of receiving a breast cancer diagnosis: A meta-analysis	22
Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate	22
Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England	22
Minimum latency effects for cancer associated with exposures to radiation or other carcinogens	22
DRP1 inhibition-mediated mitochondrial elongation abolishes cancer stemness, enhances glutaminolysis, and drives ferroptosis in oral squamous cell carcinoma	22
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer	22
Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic effic	22
Proactive breast cancer risk assessment in primary care: a review based on the principles of screening	22
Cancer cachexia: a nutritional or a systemic inflammatory syndrome?	22
Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study	21
Mammography radiomics features at diagnosis and progression-free survival among patients with breast cancer	21
Multicentric validation of nomograms based on BC-116 and BC-106 urine peptide biomarker panels for bladder cancer diagnostics and monitoring in two prospective cohorts of patients	21
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer	21
Achieving clinical success with BET inhibitors as anti-cancer agents	21
REMARK guidelines for tumour biomarker study reporting: a remarkable history	21
Advancing translational research for colorectal immuno-oncology	21
CCT5 induces epithelial-mesenchymal transition to promote gastric cancer lymph node metastasis by activating the Wnt/β-catenin signalling pathway	21
A very-hot food and beverage thermal exposure index and esophageal cancer risk in Malawi and Tanzania: findings from the ESCCAPE case–control studies	21
Phenome-wide association study (PheWAS) of colorectal cancer risk SNP effects on health outcomes in UK Biobank	21
Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging	21
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours	21
Tenascin-C expression in the lymph node pre-metastatic niche in muscle-invasive bladder cancer	21
Ultrasound-targeted microbubble destruction remodels tumour microenvironment to improve immunotherapeutic effect	21
Clinical and genomic correlates of imatinib response in melanomas with KIT alterations	21
Th2 cells inhibit growth of colon and pancreas cancers by promoting anti-tumorigenic responses from macrophages and eosinophils	21
Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit	21
C-type lectin receptor Dectin-1 blockade on tumour-associated macrophages improves anti-PD-1 efficacy in gastric cancer	21
Statin use and survival among women with ovarian cancer: an Australian national data-linkage study	20
Ferroptosis in hepatocellular carcinoma: mechanisms and targeted therapy	20
Adenoma characteristics associated with post-polypectomy proximal colon cancer incidence: a retrospective cohort study	20
Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases	20
Genomic ALK alterations in primary and relapsed neuroblastoma	20
Radiogenomics: a key component of precision cancer medicine	20
Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase	20
Precision oncology for intrahepatic cholangiocarcinoma in clinical practice	20
Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer – possible implications for immunotherapy	20
Navigating therapeutic strategies: HPV classification in head and neck cancer	20
Immunosuppressive effect of small extracellular vesicle PD-L1 is restricted by co-expression of CD80	20
Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity	20
Artificial Intelligence-based methods in head and neck cancer diagnosis: an overview	20
Single-dose intraoperative radiotherapy during lumpectomy for breast cancer: an innovative patient-centred treatment	20
Genome-scale CRISPR screen reveals neddylation to contribute to cisplatin resistance of testicular germ cell tumours	20
Matrix stiffness-induced upregulation of histone acetyltransferase KAT6A promotes hepatocellular carcinoma progression through regulating SOX2 expression	20
Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour	20
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies	19
Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression	19
Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against	19
Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label,	19
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial	19
Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab	19
Associations between obesity, metabolic health, and the risk of breast cancer in East Asian women	19
Correction to: Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort	19
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer	19
KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma	19